BioCentury
ARTICLE | Clinical News

GEM 91 antisense compound: Will start Phase IB/II trial

October 10, 1994 7:00 AM UTC

Hybridon Inc., Worcester, Mass. Product: GEM 91 antisense compound Indication: HIV-1 infection and AIDS Status: Will start Phase IB/II trial in 60 patients in the U.S. and France, in October and Novem...